Abstract
PCR testing is an important tool to mitigate outbreaks of infectious diseases. One way of increasing testing throughput is by simultaneously testing multiple samples for the presence of a pathogen, a technique known as pooling. During the current COVID-19 pandemic, rapidly testing individuals for the presence of SARS-CoV-2 is conducted in large amounts. Since testing is often a bottleneck in mitigating the spread of SARS-CoV-2, pooling is increasing in popularity. Most analyses of the error rates of pooling schemes assume that including more than a single infected sample in a pooled test does not increase the probability of a positive outcome. We challenge this assumption with experimental data and suggest a novel probabilistic model for the outcomes of pooled tests. As an application, we analyze the false-negative rates of one common pooling scheme known as Dorfman pooling. We show that the false-negative rates of Dorfman pooling increase when the prevalence of infection decreases. However, low infection prevalence is exactly the condition under which Dorfman pooling achieves highest throughput. We therefore implore the cautious use of pooling and development of pooling schemes that consider correctly accounting for tests’ error rates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by The Raymond and Beverly Sackler Post-Doctoral Scholarship and by a post-doctoral fellowship from the Tel Aviv University Center for Combating Pandemics (YD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Changed the focus of the paper.
Data Availability
Data was extracted from the paper Sample pooling for SARS-CoV-2 RT-PCR screening by De Salazar et al. cited in our paper.
